Velocity Clinical Research

JANUARY 3, 2024

The acquisition of KO-MED is Velocity’s first foray into Oncology research, which accounts for roughly 40-50% of clinical trials globally. In most cases, the participant of a clinical trial benefits from taking part, which is of great importance, especially in oncological trials. and Europe.

Clinical Trials 52

Clinical Trials Clinical Trials Clinical Research Trials 52

Scienmag

MARCH 10, 2021

Using an investigational cell therapy, Medical University of South Carolina pediatricians successfully treated two patients with multisystem inflammatory syndrome in children, a rare but life-threatening complication of COVID-19.

Trials 91

Trials Clinical Trials Clinical Trials Allergies 91

Scienmag

OCTOBER 21, 2020

Researchers have found that a class of commonly-used heart drugs may also improve patients’ responses to anti-cancer immunotherapies called PD(L)1 inhibitors, according to preliminary findings to be presented at the 32th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics, which is taking place online.

Drugs 73

Drugs Research Clinical Trials Clinical Trials 73

Scienmag

DECEMBER 1, 2020

IVIg portfolio also featured in study design poster on primary infection prophylaxis in patients with chronic lymphocytic leukemia PARAMUS, N.J.

Clinical Research 46

Clinical Research Research Clinical Trials Clinical Trials 46

The Pharma Data

NOVEMBER 4, 2020

Expanded m edical society recommendations in support of the efficacy and safety of VASCEPA : The European Society of Cardiology expanded their guidelines to recommend use of VASCEPA in treating acute coronary syndrome patients. Patients with such allergies should discontinue VASCEPA if any reactions occur. VASCEPA.

Sales 40

Sales Production Cardiology Marketing 40

Scienmag

DECEMBER 2, 2020

Research evaluates use of fibryga®, Octaplas™, and Octaplex® as investigational therapies PARAMUS, N.J.

Research 40

Research Clinical Research Clinical Trials Clinical Trials 40

XTalks

AUGUST 2, 2023

This is largely due to failed trials as a prophylaxis resulting in the European Committee for Medical Products (CHMP) recommending against the approval of Lagevrio. There was a record 34 approvals in major markets, and late-stage trials are commencing for medications including camizestrant, datopotamab deruxtecan and volrustomig.

Sales 98

Sales Manufacturing FDA Approval Life Science 98